Gender-Affirming Hormone Therapy in Primary Care Tied to Reduced Depressive Symptoms
MONDAY, March 24, 2025 -- Gender-affirming hormone therapy (GAHT) in primary care is associated with lower rates of moderate-to-severe depressive symptoms in U.S. transgender, nonbinary, and gender-diverse (TGD) adults over four years of follow-up...
MONDAY, March 24, 2025 -- Gender-affirming hormone therapy (GAHT) in primary care is associated with lower rates of moderate-to-severe depressive symptoms in U.S. transgender, nonbinary, and gender-diverse (TGD) adults over four years of follow-up...
